Perhexiline ( DrugBank: Perhexiline )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
58	肥大型心筋症	5
272	進行性骨化性線維異形成症	1

58. 肥大型心筋症

臨床試験数 : 126 / 薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04426578 (ClinicalTrials.gov)	December 1, 2020	14/5/2020	Role of Perhexiline in Hypertrophic Cardiomyopathy	Randomised Controlled Trial of pErhexiline on regreSsion Of Left Ventricular hypErtrophy (LVH) in Patients With Symptomatic Hypertrophic CardioMyopathy (RESOLVE-HCM)	Hypertrophic Cardiomyopathy	Drug: Perhexiline;Other: Placebo	Flinders University	NULL	Recruiting	18 Years	N/A	All	60	Phase 2	Australia
2	NCT02862600 (ClinicalTrials.gov)	August 1, 2016	8/8/2016	Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure	A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular Function	Cardiomyopathy, Hypertrophic;Cardiomyopathy, Hypertrophic, Familial	Drug: Perhexiline;Device: Use of bioanalytical assay to monitor plasma levels of perhexiline	Heart Metabolics Limited	NULL	Terminated	18 Years	N/A	All	35	Phase 2	United States
3	NCT02431221 (ClinicalTrials.gov)	July 22, 2015	27/4/2015	Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure	A Study on the Efficacy, Safety, and Tolerability of Perhexiline Maleate in Subjects With Hypertrophic Cardiomyopathy and Moderate-To-Severe Heart Failure	Hypertrophic Cardiomyopathy	Drug: Perhexiline;Drug: Placebo	Heart Metabolics Limited	NULL	Withdrawn	18 Years	N/A	All	0	Phase 3	NULL
4	NCT00500552 (ClinicalTrials.gov)	December 2006	10/7/2007	Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy	Metabolic Alteration With Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy (METAL-HCM Study)	Hypertrophic Cardiomyopathy	Drug: Perhexiline/Placebo	University Hospital Birmingham	British Heart Foundation;University College London Hospitals;University of Oxford	Completed	18 Years	80 Years	Both	44	Phase 2	United Kingdom
5	EUCTR2005-000755-15-GB (EUCTR)	25/10/2005	27/05/2005	Perhexiline therapy in patients with Hypertrophic Cardiomyopathy	Perhexiline therapy in patients with Hypertrophic Cardiomyopathy	Hypertrophic Cardiomyopathy	Product Name: Pexsig INN or Proposed INN: Perxexiline	University Hospital of Birmingham Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50		United Kingdom

272. 進行性骨化性線維異形成症

臨床試験数 : 39 / 薬物数 : 38 - (DrugBank : 7) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 95

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000019348	2010/07/01	14/10/2015	Approved calcium channel blocker in the treatment of fibrodysplasia ossificans progressiva (FOP)	Approved calcium channel blocker in the treatment of fibrodysplasia ossificans progressiva (FOP) - Perhexiline maleate treatment for FOP	fibrodysplasia ossificans progressiva	oral administration of perhexiline maleate for one year	Nagoya University Graduate School of Medicine	NULL	Complete: follow-up complete	15years-old	65years-old	Male and Female	5	Phase 1,2	Japan